WAYNE, Pa., May 03, 2021 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 15, 2021 to shareholders of record at the close of business on […]
Other News
Sequana Medical Announces New Share Capital Amount and New Number of Shares
Ghent, Belgium, 3 May 2021 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces in accordance with Article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in […]
Zynex Announces 2021 First Quarter Earnings
ENGLEWOOD, Colo., April 29, 2021 /PRNewswire/ — 2021 First Quarter Revenue increased 58% year over year to $24.1 million Orders increased 140% Net loss of $0.7 million; GAAP loss per share $0.02 Adjusted EBITDA loss $0.4 million Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for […]
CryoLife Reports First Quarter 2021 Financial Results
ATLANTA, April 29, 2021 /PRNewswire/ — First Quarter and Recent Business Highlights: Achieved total revenues of $71.1 million in the first quarter 2021 versus $66.4 million in the first quarter of 2020, an increase of 7% on a GAAP basis and 3% on a non-GAAP proforma constant currency basis Net loss was ($3.1) million, or ($0.08) per share, in […]
Innovative Medical Communications Announces Launch of Outpatient Endovascular & Surgical Journal
WEST CHESTER, Pa., April 29, 2021 /PRNewswire/ — Innovative Medical Communications is delighted to announce the launch of Outpatient Endovascular & Surgical Journal, www.oesj.info, a new publication providing health-care communications for clinicians and fellows who have a clinical focus on outpatient endovascular and surgical procedures. Through clinical manuscripts, technology assessments, expert interviews, topical discussion […]
Merit Medical Reports Results for Quarter Ended March 31, 2021
April 29, 2021 16:05 ET | Source: Merit Medical Systems, Inc. Q1 2021 reported revenue of $248.9 million, up 2.2% compared to Q1 2020 Q1 2021 constant currency revenue, organic* up 0.6% compared to Q1 2020 Q1 2021 GAAP EPS of $0.19, compared to GAAP loss per share of ($0.06) in Q1 […]
Overcoming the Treatment-Risk Paradox for Intensive Blood Pressure Care
New editorial published in the Journal of the American College of Cardiology compares cardiovascular disease prevention treatments MANHASSET, N.Y.–(BUSINESS WIRE)–Patients most likely to benefit from intensive systolic blood pressure treatment (SBP) versus standard treatment to reduce cardiovascular disease (CVD) may also be at risk for adverse events (AE). In an […]
Artio Medical Closes Tranche of $12 Million in Series A Financing
Company to accelerate clinical testing and prepare for commercialization of its broad portfolio products Prairie Village, KS – April 29, 2021 – Artio Medical, Inc., a medical device company developing innovative products for the peripheral vascular, neurovascular, and structural heart markets, announced today the closing of an additional $12 million […]
CorWave Presents an Unprecedented Chronic In Vivo Study at the 41st Annual Meeting of the International Society of Heart and Lung Transplantation
CLICHY, France–(BUSINESS WIRE)–CorWave, a French medical device company committed to the fight against heart failure, unveiled an unprecedented study on the performance of its implantable heart pump at the 41st Annual Meeting of the International Society for Heart and Lung Transplantation (ISHLT). The company presented the first ever study demonstrating […]
AtriCure’s EPi-Sense System Approved by FDA for Treatment of Long-Standing Persistent Afib Patients
FDA approval results in the only label of its kind for more than 3 million patients in the United States, significantly expanding AtriCure’s addressable market Superiority trial showed a 29% difference in effectiveness at 12 months and a 35% difference in effectiveness at 18 months for long-standing persistent Afib patients. Study […]



